Trevi Therapeutics, Inc.
TRVI
$6.47
$0.121.89%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 1.82% | -12.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.09% | 6.00% | |||
| Operating Income | 13.09% | -6.00% | |||
| Income Before Tax | 14.12% | -7.39% | |||
| Income Tax Expenses | 151.61% | -287.50% | |||
| Earnings from Continuing Operations | 13.80% | -7.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.80% | -7.21% | |||
| EBIT | 13.09% | -6.00% | |||
| EBITDA | 13.14% | -6.04% | |||
| EPS Basic | 17.60% | -6.96% | |||
| Normalized Basic EPS | 17.95% | -7.06% | |||
| EPS Diluted | 17.60% | -6.96% | |||
| Normalized Diluted EPS | 17.95% | -7.06% | |||
| Average Basic Shares Outstanding | 4.67% | 0.24% | |||
| Average Diluted Shares Outstanding | 4.67% | 0.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||